HIGHLIGHTS
- who: Tara M. Rogers from the School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA have published the Article: Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates, in the Journal: (JOURNAL) of 21/Dec/2022
- what: The authors aimed to characterize and contrast the in vitro activity of these agents against genetically diverse KPC-Kp clinical isolates. The authors compared the MICs and in_vitro killing activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/ vaborbactam against KPC . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.